RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
Provided By GlobeNewswire
Last update: Nov 14, 2024
Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels
Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial; Trial Moving Towards Next Interim Analysis and Full Enrollment
Read more at globenewswire.com
